An Early Phase 1 interventional study of Virtual Assistant in Stroke, Guillain-Barre Syndrome and Facial Palsy, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Early Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Stroke with a site in Argentina — 9 open to participants now, 12 under way, 3 of them phase 3. Stroke · Argentina.
Among the 50 studies in Stroke with a site in Argentina, this one is the 37th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1, and was the 43rd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 50 studies in Stroke with a site in Argentina are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Argentina, Australia, Austria and 35 more countries
Ages 50+
Regeneron Pharmaceuticals · Sites in Argentina, United States, Brazil and 1 more country
Ages 18+
Ramos Mejía Hospital · Sites in Argentina
Ages 16+
McMaster University · Sites in Argentina, Canada
Ages 18+
Philips Clinical & Medical Affairs Global · Sites in Argentina, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 5,390 across the 37 interventional studies, 535 across the 13 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 50 have an industry lead sponsor. The 10 most frequent:
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia has 3 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Stroke with a site in Argentina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07475611Fundación para la Lucha contra las Enfermedades Neurológicas de la InfanciaEffectiveness of an Interactive Screen in the Rehabilitation of Neglect in Adults With Subacute Stroke: A Randomized Controlled Trial in Argentina. | 2026-12-01 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT06964724VesalioNeVa Retrospective Comparative SR Study | 2027-02-01 |
| NCT07175428Regeneron PharmaceuticalsSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | 2027-02-09 |
| NCT04701684Philips Clinical & Medical Affairs GlobalWE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 50 studies in Stroke with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines the use of an AI-powered virtual assistant for quickly identifying and handling neurological emergencies, particularly in places with limited medical resources. The research aimed to check if this AI tool is safe and accurate enough to move on to more advanced testing stages. In a first-of-its-kind trial, the virtual assistant was tested with patients having urgent neurological issues. Neurologists first reviewed the AI's recommendations using clinical records and then assessed its performance directly with patients. The findings were as follows: neurologists agreed with the AI's decisions nearly all the time, and the AI outperformed earlier versions of Chat GPT in every tested aspect. Patients and doctors found the AI to be highly effective, rating it as excellent or very good in most cases. This suggests the AI could significantly enhance how quickly and accurately neurological emergencies are dealt with, although further trials are needed before it can be widely used.
Background and Objectives: Neurological emergencies pose significant challenges in medical care, especially in resource-limited countries. Artificial Intelligence (AI), particularly health chatbots, offers a promising solution. However, rigorous validation is required to ensure safety and accuracy. The objective of our work is to evaluate the diagnostic accuracy and resolution effectiveness of an AI-powered virtual assistant designed for the triage of emergency neurological pathologies, to ensure the minimum standard of safety that allows for the progression to successive validation tests.
Methods: This Phase 1 trial evaluates the performance of an AI-powered virtual assistant for emergency neurological triage. Ten patients over 18 years old with urgent neurological pathologies were selected. In the first stage, nine neurologists assessed the safety of the virtual assistant using their clinical records. In the second part, the assistant's accuracy when used by patients was evaluated. Finally, its performance was compared with Chat GPT 3.5 and 4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients answer question with a virtual assistant about their recent visit to the ER.
Diagnostic Test: Virtual Assistant
Patients answer question with ChatGPT about their recent visit to the ER.
Diagnostic Test: Virtual Assistant
Patients answer question with ChatGPT about their recent visit to the ER.
Diagnostic Test: Virtual Assistant
Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
Diagnostic performance
Refers to the accuracy and effectiveness of medical tests or diagnostic tools in correctly identifying a disease or condition in patients. Syndromic diagnosis agreement: evaluating neurologists considered a syndromic diagnosis accurate when AI tools could identify a condition based on a set of commonly coexisting signs and symptoms, rather than identifying a specific disease. This method is applied when the precise disease causing the symptoms is not immediately identifiable, allowing healthcare providers to effectively monitor and treat the patient's presenting symptoms. Differential diagnosis agreement: a differential diagnosis was considered accurate when the differentials provided by each AI tool matched those presented by the participants. The gold standard for diagnosis was considered to be the one given in the emergency department, unchanged over a one-month period.
Time frame: The first interaction between participants and the virtual assistant occurred within less than a year after the event. Outcome measures were evaluated immediately after the interaction between patients and the virtual assistant.
Appropriate medical conduct or recommendation
Case resolution was evaluated based on appropriate medical conduct or recommendation, categorizing 1) urgency as immediate, 2) short-term (within 48 hours), 3) or non-urgent. The recommendations provided by each AI tool were assessed based on information gathered from clinical histories and input from participants. The gold standard of appropriate medical conduct or recommendation was considered to be that given in the emergency department, with no changes over a period of one month.
Time frame: The first interaction between participants and the virtual assistant occurred within less than a year after the event. Outcome measures were evaluated immediately after the interaction between patients and the virtual assistant.
Assessment of Usability and Satisfaction
Usability was measured by the time and number of questions needed for final diagnosis and resolution, both by neurologists and participants. For Chat GPT, we evaluated the time taken to draft the consultation reason. A satisfaction scale from 1 to 5 was implemented, with 1 indicating a negative experience ("poor", potentially risky for the patient) and 5 highly positive ("excellent", potentially surpassing non-specialized human triage). A simple yes/no survey was also applied to participants, asking about the comprehensibility of the assistant's questions, the adequacy of referral according to urgency, and whether they considered the assistant could replace non-specialized triage or reduce emergency arrival time.
Time frame: The first interaction between participants and the virtual assistant occurred within less than a year after the event. Outcome measures were evaluated immediately after the interaction between patients and the virtual assistant.
Plan to share: No — We will not share IPD
Ran from Oct 2023 to primary completion in Jan 2024, 3 months.
Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's 3 months is below that.
Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia